-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (Favezelimab + Pembrolizumab) in Metastatic Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Favezelimab + Pembrolizumab) in Metastatic Renal Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Favezelimab + Pembrolizumab) in Metastatic Renal Cell Carcinoma...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lutetium Lu 177 Vipivotide Tetraxetan in Hormone-Sensitive Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lutetium Lu 177 Vipivotide Tetraxetan in Hormone-Sensitive Prostate Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lutetium Lu 177 Vipivotide Tetraxetan in...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CD33 NKE in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CD33 NKE in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CD33 NKE in Relapsed Multiple Myeloma Drug Details: CD33 NKE...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OPN-2853 in Myelofibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OPN-2853 in Myelofibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OPN-2853 in Myelofibrosis Drug Details: PLX-2853 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TPST-1495 in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TPST-1495 in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TPST-1495 in Endometrial Cancer Drug Details: TPST-1495 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aldesleukin in Amyotrophic Lateral Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aldesleukin in Amyotrophic Lateral Sclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aldesleukin in Amyotrophic Lateral Sclerosis Drug Details: Aldesleukin (Proleukin) is an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Docetaxel in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Docetaxel in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Docetaxel in Non Muscle Invasive...
-
Product Insights
Leiomyosarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Leiomyosarcoma - Drugs In Development, 2023’, provides an overview of the Leiomyosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leiomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Adrenal Gland Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Adrenal Gland Cancer - Drugs In Development, 2023’, provides an overview of the Adrenal Gland Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Adrenal Gland Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...